PURPOSE: The following experiments determined whether intravenous infusions of Cereport enhance delivery of chemotherapeutics and prolong survival in rats with metastatic tumors in the brain. METHODS: Autoradiography and scintillation were used to examine uptake of the lipophilic (paclitaxel and carmustine) and the hydrophilic (carboplatin) chemotherapeutic agents, as well as the large hydrophilic marker, 70 kDa dextran. Cereport was also tested in combination with the chemotherapeutic drugs carboplatin, vinorelbine, gemcitabine and carmustine to determine if Cereport could enhance the survival benefit beyond that provided by chemotherapy alone. RESULTS: Cereport enhanced the uptake of carboplatin and dextran, but not paclitaxel or carmustine. The pattern of Cereport's uptake effect with carboplatin revealed that Cereport selectively increased the proportion of highly permeable regions. Survival was significantly enhanced when Cereport was combined with either carboplatin, vinorelbine, or gemcitabine, but not carmustine, compared to each chemotherapeutic agent alone. CONCLUSIONS: These data provide the first evidence that Cereport, or any receptor-mediated approach intended to enhance the permeability of the blood-brain tumor barrier, can increase the delivery hydrophilic drugs to metastatic tumors in the brain, increasing survival in tumor-bearing rats.
PURPOSE: The following experiments determined whether intravenous infusions of Cereport enhance delivery of chemotherapeutics and prolong survival in rats with metastatic tumors in the brain. METHODS: Autoradiography and scintillation were used to examine uptake of the lipophilic (paclitaxel and carmustine) and the hydrophilic (carboplatin) chemotherapeutic agents, as well as the large hydrophilic marker, 70 kDa dextran. Cereport was also tested in combination with the chemotherapeutic drugs carboplatin, vinorelbine, gemcitabine and carmustine to determine if Cereport could enhance the survival benefit beyond that provided by chemotherapy alone. RESULTS: Cereport enhanced the uptake of carboplatin and dextran, but not paclitaxel or carmustine. The pattern of Cereport's uptake effect with carboplatin revealed that Cereport selectively increased the proportion of highly permeable regions. Survival was significantly enhanced when Cereport was combined with either carboplatin, vinorelbine, or gemcitabine, but not carmustine, compared to each chemotherapeutic agent alone. CONCLUSIONS: These data provide the first evidence that Cereport, or any receptor-mediated approach intended to enhance the permeability of the blood-brain tumor barrier, can increase the delivery hydrophilic drugs to metastatic tumors in the brain, increasing survival in tumor-bearing rats.
Authors: W L Monsky; D Fukumura; T Gohongi; M Ancukiewcz; H A Weich; V P Torchilin; F Yuan; R K Jain Journal: Cancer Res Date: 1999-08-15 Impact factor: 12.701
Authors: R T Bartus; P J Elliott; R L Dean; N J Hayward; T L Nagle; M R Huff; P A Snodgrass; D G Blunt Journal: Exp Neurol Date: 1996-11 Impact factor: 5.330
Authors: D F Emerich; P Snodgrass; R Dean; M Agostino; B Hasler; M Pink; H Xiong; B S Kim; R T Bartus Journal: Br J Cancer Date: 1999-06 Impact factor: 7.640
Authors: Rafael C Dutra; Daniela F P Leite; Allisson F Bento; Marianne N Manjavachi; Eliziane S Patrício; Cláudia P Figueiredo; João B Pesquero; João B Calixto Journal: PLoS One Date: 2011-11-22 Impact factor: 3.240
Authors: Hemant Sarin; Ariel S Kanevsky; Steve H Fung; John A Butman; Robert W Cox; Daniel Glen; Richard Reynolds; Sungyoung Auh Journal: J Transl Med Date: 2009-05-13 Impact factor: 5.531